Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184963 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP1B1CYP17A1 | |
| SCHEMBL28263240 | 0.79 | CYP19A1 (0.61) | CYP19A1CYP1B1CYP17A1 | |
| SCHEMBL514563 | 0.78 | CYP19A1 (0.54) | CYP19A1CYP1B1CYP17A1 | |
| SCHEMBL6246806 | 0.76 | CYP19A1 (0.55) | CYP19A1CYP1B1CYP17A1 | |
| SCHEMBL26807214 | 0.76 | CYP19A1 (0.67) | CYP19A1CYP1B1 | |
| SCHEMBL32677703 | 0.76 | CYP19A1 (0.67) | CYP19A1CYP1B1 | |
| SCHEMBL4885211 | 0.76 | CYP19A1 (0.67) | CYP19A1CYP1B1 | |
| SCHEMBL606825 | 0.76 | CYP19A1 (0.67) | CYP19A1CYP1B1 | |
| SCHEMBL4871949 | 0.74 | CYP19A1 (0.53) | CYP19A1CYP1B1GRIN2BGRIN2A | |
| SCHEMBL3130653 | 0.74 | CYP17A1 (0.69) | CYP19A1CYP1B1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | CYP19A1 4139/4885CYP1B1 4754/4885CYP17A1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.